Cantor Fitzgerald set a $35.00 price target on Collegium Pharmaceutical (NASDAQ:COLL) in a research report sent to investors on Friday, TipRanks reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
Several other research firms also recently commented on COLL. BidaskClub raised Collegium Pharmaceutical from a buy rating to a strong-buy rating in a research report on Saturday, January 5th. Zacks Investment Research raised Collegium Pharmaceutical from a sell rating to a hold rating in a research report on Tuesday, March 5th. ValuEngine raised Collegium Pharmaceutical from a sell rating to a hold rating in a research report on Thursday, February 28th. SunTrust Banks began coverage on Collegium Pharmaceutical in a research report on Tuesday, March 19th. They issued a buy rating and a $22.00 target price on the stock. Finally, Janney Montgomery Scott began coverage on Collegium Pharmaceutical in a research report on Friday, April 12th. They issued a buy rating and a $29.00 target price on the stock. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Collegium Pharmaceutical currently has a consensus rating of Buy and a consensus target price of $28.00.
Collegium Pharmaceutical stock opened at $14.99 on Friday. Collegium Pharmaceutical has a 12 month low of $13.10 and a 12 month high of $28.91. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.21 and a current ratio of 1.26. The company has a market capitalization of $500.25 million, a PE ratio of -12.60 and a beta of 0.32.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 EPS for the quarter, beating the consensus estimate of ($0.38) by $0.65. Collegium Pharmaceutical had a negative return on equity of 41.12% and a negative net margin of 13.95%. The company had revenue of $73.40 million for the quarter, compared to the consensus estimate of $72.71 million. During the same quarter in the prior year, the business earned ($0.54) earnings per share. The firm’s revenue for the quarter was up 579.6% on a year-over-year basis. On average, analysts anticipate that Collegium Pharmaceutical will post -0.31 EPS for the current year.
In related news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $17.17, for a total transaction of $429,250.00. Following the sale, the director now owns 227,362 shares of the company’s stock, valued at $3,903,805.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 75,000 shares of company stock worth $1,176,750 in the last three months. 8.08% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in COLL. First Quadrant L P CA bought a new stake in Collegium Pharmaceutical during the first quarter worth $36,000. Meeder Asset Management Inc. lifted its stake in Collegium Pharmaceutical by 644.8% during the fourth quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock worth $62,000 after purchasing an additional 3,179 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in Collegium Pharmaceutical by 67,855.6% during the first quarter. BNP Paribas Arbitrage SA now owns 6,116 shares of the specialty pharmaceutical company’s stock worth $93,000 after purchasing an additional 6,107 shares during the last quarter. Oregon Public Employees Retirement Fund bought a new stake in Collegium Pharmaceutical during the fourth quarter worth $103,000. Finally, Virginia Retirement Systems ET AL bought a new stake in Collegium Pharmaceutical during the first quarter worth $160,000.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Recommended Story: What is a support level?
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.